Alisertib
- Generic Name
- Alisertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H20ClFN4O4
- CAS Number
- 1028486-01-2
- Unique Ingredient Identifier
- T66ES73M18
- Background
Alisertib is a novel aurora A kinase inhibitor under investigation for the treatment of various forms of cancer.
- Indication
For the treatment of various forms of cancer.
- Associated Conditions
- -
- Associated Therapies
- -
MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-09-16
- Last Posted Date
- 2019-09-20
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02551055
Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2015-08-21
- Last Posted Date
- 2021-05-26
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 26
- Registration Number
- NCT02530619
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-02-20
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT02367352
A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2014-12-30
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 81
- Registration Number
- NCT02327169
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors
- Conditions
- Interventions
- First Posted Date
- 2014-12-18
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 14
- Registration Number
- NCT02319018
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
- First Posted Date
- 2014-11-18
- Last Posted Date
- 2022-10-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT02293005
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-10-08
- Last Posted Date
- 2019-09-20
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02259010
Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 10
- Registration Number
- NCT02219789
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function
- Conditions
- Interventions
- First Posted Date
- 2014-08-12
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT02214147
Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- US Oncology Research
- Target Recruit Count
- 169
- Registration Number
- NCT02187991
- Locations
- 🇺🇸
22 Sites, Including Dallas And Austin, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.